Unisys has been recognized on Business Insider's 2027 list of 500 America's Most Innovative Businesses, earning a 4.5 out of 5-star rating for its reputation, technological impact, and investment in research and development. This accolade highlights Unisys's commitment to innovation, combining AI and expertise to deliver client solutions. The company was selected from 4,000 publicly traded U.S. firms and ranked among the top 15 in the IT Services & IT Consulting category. This recognition follows other recent honors, reinforcing Unisys's position as a leader in technology innovation.
Unisys recognition on Business Insider's 2027 list provides context for technology sector investors. For readers following technology stocks, here is Pluang's market snapshot as of Sep 28, 2026 20:31 WIB: out of 150 priced US technology stocks, 13 rose and 131 fell. Notable movers include AXTI at USD 76.00 with a -3.72% change, EGHT at USD 2.22 down 3.48%, and FIRY at USD 12.00 down 3.38%.
Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....
Accenture's stock surged 37.6% recently, driven by rising demand for AI services and new AI-focused offerings. The company outpaced industry growth and secured 100 new clients for advanced AI projects in one quarter. An analyst raised the price targe...
SpaceX, trading near $148 per share with a market cap of about $1.95 trillion, is preparing for Starship's first orbital mission and the deployment of its first operational Starlink V3 satellites. This milestone is key for expanding Starlink's global...
Argus Research initiated coverage on 10x Genomics with a Buy rating and a $110 price target, suggesting a 28% upside from its current price of around $85. The stock shows strong momentum, trading well above its 50-day and 200-day moving averages. How...
Morgan Stanley reaffirmed an "Overweight" rating on Cullen/Frost Bankers, Inc., raising its price target to $201, signaling confidence in the bank's prospects. Major institutional investors like State Street Corp and BlackRock have increased or initi...
